We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Tests Could Reveal Early Signs of Cancer and Other Diseases

By LabMedica International staff writers
Posted on 24 Oct 2024

Early detection is essential for effectively treating diseases such as cancer, yet not everyone has convenient access to screening tools. More...

For issues affecting the genitourinary (GU) tract, which includes the kidneys, prostate, and bladder, healthcare providers typically employ a combination of screening methods, including blood tests, imaging, and physical examinations. Researchers are now developing an even simpler tool for early disease screening—urine analysis.

A new study by a team of scientists, including researchers from the University of Texas at Arlington (UTA; Arlington, TX, USA), has shown that analyzing RNA (a type of genetic material) and other substances present in urine can indicate changes in cell types, potentially revealing early signs of cancer and other diseases. This approach could assist clinicians in identifying issues earlier when they are more easily treatable without requiring invasive procedures. In the study, the researchers collected urine samples from two groups: healthy individuals and those with kidney stones. They extracted two types of RNA from the urine—cell-free RNA, which is suspended freely in the urine, and sediment RNA, derived from solid particles. The RNA types were sequenced and analyzed, comparing samples from healthy individuals with those from patients who had kidney stones.

The findings of the study were published in Clinical Chemistry, a journal of the Association for Diagnostics & Laboratory Medicine (ADLM), revealing that advanced urine analyses could identify cellular patterns that indicate the presence of disease. The next phase of the research focuses on employing advanced machine learning techniques to further refine the differences detectable when comparing the RNA and protein signatures of healthy individuals to those diagnosed with diseases. The researchers aim to identify additional biomarkers that could facilitate the development of simpler, less invasive diagnostic methods in the future.

“We’re excited about this new research as it may lead to new, easier screening tools that can help detect diseases of the bladder, kidneys, and prostate,” said Joseph Buonomo, assistant professor of chemistry at UTA and an author of the study. “Although our patient cohort was small, it lays the groundwork for development of a type of ‘non-invasive liquid biopsy’ that will be used to track the progression of ailments like kidney stones, diabetes, and cancer using urine instead of surgical specimens.” 

Related Links:
University of Texas at Arlington


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.